| Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and a … R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ... The Lancet Infectious Diseases 22 (4), 473-482, 2022 | 95 | 2022 |
| Safety, tolerability and immunogenicity of Biological E’s CORBEVAX™ vaccine in children and adolescents: A prospective, randomised, double-blind, placebo controlled, phase-2/3 … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, RR Mogulla, PV Suneetha, ... Vaccine 40 (49), 7130-7140, 2022 | 26 | 2022 |
| Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase-3, single blind, multicentre, randomized … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, PV Suneetha, ... Human Vaccines & Immunotherapeutics 19 (1), 2203632, 2023 | 13 | 2023 |
| Cellular immune responses are preserved and may contribute to Chadox1 ChAdOx1 nCoV-19 vaccine effectiveness against infection due to SARS-CoV-2 B· 1· 617· 2 delta variant … R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ... | 13 | 2021 |
| Immunogenic superiority and safety of Biological E’s CORBEVAX™ vaccine compared to COVISHIELD™(ChAdOx1 nCoV-19) vaccine studied in a phase III, single blind, multicenter … S Thuluva, V Paradkar, K Turaga, SR Gunneri, V Yerroju, R Mogulla, ... Medrxiv, 2022.03. 20.22271891, 2022 | 11 | 2022 |
| Proinflammatory innate cytokines and distinct metabolomic signatures shape the T cell response in active COVID-19 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, MR Tripathy, ... Vaccines 10 (10), 1762, 2022 | 8 | 2022 |
| Innate immune response and distinct metabolomic signatures together drive and shape the SARS-CoV-2-specific T cell response during COVID-19 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, M Tripathi, U Madan, ... bioRxiv, 2022 | 2 | 2022 |
| A quest for universal anti-SARS-CoV-2 T cell assay: systematic review, meta-analysis, and experimental validation A Binayke, A Zaheer, S Vishwakarma, S Singh, P Sharma, ... npj Vaccines 9 (1), 3, 2024 | | 2024 |
| Immunogenicity and safety of Biological E’s CORBEVAX™ vaccine as a heterologous booster dose in adult volunteers previously vaccinated with two doses of either COVISHIELD™ or … S Thuluva, V Paradkar, SR Gunneri, V Yerroju, R Mogulla, PV Suneetha, ... medRxiv, 2022.12. 29.22284049, 2023 | | 2023 |
| Control of CD4+ T Cell Differentiation and Function by PI3K Isoforms B Cameron, SA Zaheer, M Dominguez-Villar PI3K and AKT Isoforms in Immunity: Mechanisms and Therapeutic Opportunities …, 2022 | | 2022 |
| Proinflammatory innate cytokines and metabolomic signatures predict T cell response in active COVID-19 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, M Tripathi, U Madan, ... bioRxiv, 2022.03. 11.483930, 2022 | | 2022 |
| Proinflammatory Innate Cytokines and Distinct Metabolomic Signatures Shape the T Cell Response in Active COVID-19. Vaccines 2022, 10, 1762 A Binayke, A Zaheer, J Dandotiya, SK Gupta, S Mani, MR Tripathy, ... s Note: MDPI stays neutral with regard to jurisdictional claims in published …, 2022 | | 2022 |
| Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B. 1.617. 2) variant surge in India: a test-negative, case-control study and a … R Thiruvengadam, A Awasthi, G Medigeshi, S Bhattacharya, S Mani, ... Lancet Infect Dis, 473-482, 2022 | | 2022 |
